Comparing SG&A Expenses: Amgen Inc. vs Insmed Incorporated Trends and Insights

SG&A Expenses: A Tale of Two Biotech Giants

In the competitive world of biotechnology, understanding the financial strategies of industry leaders is crucial. Amgen Inc. and Insmed Incorporated, two prominent players, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.

Amgen Inc.: Steady Growth

From 2014 to 2023, Amgen's SG&A expenses have consistently increased, peaking at approximately $6.2 billion in 2023. This represents a 31% rise from 2014, reflecting Amgen's strategic investments in marketing and administration to maintain its market dominance.

Insmed Incorporated: Rapid Expansion

In contrast, Insmed's SG&A expenses have surged by over 1,000% during the same period, reaching around $345 million in 2023. This dramatic increase underscores Insmed's aggressive expansion efforts and its commitment to scaling operations.

These trends highlight the differing strategies of these biotech firms, offering valuable insights into their operational priorities and market positioning.